Budesonide add-on therapy improves markers of disease activity but fails to improve histology

April 13, 2018, European Association for the Study of the Liver

The addition of budesonide is associated with clinically meaningful improvements in biochemical markers of disease activity but no improvement in liver histology in high-risk patients with primary biliary cholangitis (PBC) experiencing a sub-optimal response to ursodeoxycholic acid (UDCA), according to the results of a study presented today. The placebo-controlled study, which randomized 62 patients with PBC, was terminated early because of slow recruitment and as a result, insufficient power to detect a significant histological difference between treatment groups.

PBC is an that is characterized by the progressive destruction of the small bile ducts, resulting in intrahepatic cholestasis, parenchymal injury, and, ultimately, end-stage . The condition typically occurs in middle-aged women, with features frequently including fatigue, pruritis, jaundice, xanthomas, osteoporosis, and dyslipidaemia. Ursodeoxycholic acid is the first-line therapy for PBC; however, up to 40% of patients have an insufficient response to this therapy. Second-line licensed therapy is with obeticholic acid. Previous studies evaluating the combination of budesonide and UDCA in patients with PBC reported promising results, although relevant budesonide toxicity was reported in patients with late-stage disease.

The study presented today at The International Liver Congress 2018 in Paris, France, represents an important, long-awaited, placebo-controlled trial evaluating patients with PBC at high risk of progression. Patients were required to have histologically confirmed PBC and inflammatory activity according to the Ishak score, failure to achieve serum alkaline phosphatase (ALP) <1.5 x the upper limit of normal after at least 6 months of UDCA therapy, and a high risk of disease progression. Patients were randomized to receive either budesonide 9 mg/day or placebo in addition to UDCA for the duration of the study, with the possibility to taper budesonide down to 6 mg/day upon normalization of aspartate aminotransferase (AST). The primary efficacy endpoint was improvement in liver histology with respect to inflammation (an improvement of at least 3 points in the Ishak score or no inflammatory activity) and no progression of fibrosis.

After a mean treatment duration of 25.3 months, the primary histological endpoint in an intention-to-treat analysis was not met, with 11/26 patients (42.3%) in the budesonide group and 5/17 patients (29.4%) in the placebo group having an improvement in liver histology (p=0.225). However, normalization of serum ALP occurred in 14/40 patients (35.0%) in the budesonide group and in 2/22 patients (9.1%) in the placebo group (p=0.023). Serious adverse events occurred in 10 and seven patients in the budesonide and placebo groups, respectively. Similar numbers of patients reported adverse events in each treatment group; adverse drug reactions were reported for 24 patients (60%) in the budesonide group and eight patients (36%) in the placebo group.

'Our study found that add-on budesonide produced clinically meaningful improvements in biochemical markers of disease activity that, unfortunately, did not translate into improved ', said Professor Gideon Hirschfield from the University of Birmingham in the UK. 'The overall safety and tolerability of long-term budesonide treatment in this population was acceptable and in keeping with clinical experience'.

Professor Hirschfield believes that the recruitment challenges that led to a lack of statistical power for the primary histological endpoint in this study are relevant for future studies in PBC. 'Nevertheless', he says, 'the observation that liver biochemical improvements were seen with add-on budesonide is consistent with prior trial data and treatment goals'.

'Study recruitment inevitably pre-dated second-line licensed therapy with obeticholic acid', he noted. 'However, our results suggest that after licensed therapy has been offered to patients, there may be individuals in whom there is a high risk of progression and for whom the addition of budesonide to anti-cholestatic therapy will produce biochemical improvements in disease activity'.

'Clinical research to improve the therapeutic options available for primary biliary cholangitis is key, and studies such as these are important to help understand the measures needed to individualize treatment protocols by identifying the hallmark clinical features of response', said Prof. Marco Marzioni from the University Hospital of Ancona, Italy, and EASL Governing Board Member. 'This study also highlights the complexity of research focusing on cholangiopathies, and how this is impacted by the small pool of patients that are eligible to enter clinical trials. Yet, hepatologists do not leave those behind, and continue to work on developing more effective clinical management options'.

Explore further: Long-term obeticholic acid treatment leads to reversal or stabilization of fibrosis/cirrhosis in patients with PBC

Related Stories

Long-term obeticholic acid treatment leads to reversal or stabilization of fibrosis/cirrhosis in patients with PBC

April 13, 2018
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid (OCA) leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis ...

Phase 2 studies of two novel treatments for primary biliary cholangitis report encouraging results

April 13, 2018
Preliminary results from two ongoing Phase 2 studies of novel agents under investigation for the treatment of primary biliary cholangitis (PBC) have suggested promising efficacy, safety and tolerability profiles in patients ...

Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated

April 22, 2017
The results of the BEZURSO study, presented today, found that bezafibrate in combination with UDCA normalised prognostic markers of liver disease in patients with primary biliary cholangitis (PBC) with an inadequate response ...

NGM282—an engineered analogue of FGF19—shows promise in patients with primary sclerosing cholangitis

April 13, 2018
The fibroblast growth factor 19 (FGF19) engineered analogue, NGM282, inhibits bile acid synthesis, decreases markers of hepatic inflammation, and significantly improves markers of fibrosis in patients with primary sclerosing ...

Statins associated with reduced morbidity and mortality in patients with primary sclerosing cholangitis

April 12, 2018
A large register-based study conducted in Sweden has found that statins are associated with a markedly reduced risk of all-cause mortality, liver transplantation, liver cancer, and variceal bleeding in patients with primary ...

FDA approves ocaliva for primary biliary cholangitis

June 1, 2016
(HealthDay)—Ocaliva (obeticholic acid) has been approved by the U.S. Food and Drug Administration to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response ...

Recommended for you

Research finds new mechanism that can cause the spread of deadly infection

April 20, 2018
Scientists at the University of Birmingham have discovered a unique mechanism that drives the spread of a deadly infection.

Selection of a pyrethroid metabolic enzyme CYP9K1 by malaria control activities

April 20, 2018
Researchers from LSTM, with partners from a number of international institutions, have shown the rapid selection of a novel P450 enzyme leading to insecticide resistance in a major malaria vector.

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Low-cost anti-hookworm drug boosts female farmers' physical fitness

April 19, 2018
Impoverished female farm workers infected with intestinal parasites known as hookworms saw significant improvements in physical fitness when they were treated with a low-cost deworming drug. The benefits were seen even in ...

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

Super-superbug clones invade Gulf States

April 18, 2018
A new wave of highly antibiotic resistant superbugs has been found in the Middle East Gulf States, discovered by University of Queensland researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.